Six-month, double-blind comparison of isoxicam with buffered aspirin in rheumatoid arthritis.
The results of a six-month, double-blind comparison of isoxicam (Maxicam), 200 mg once a day, with buffered aspirin, 3,600 mg per day (900 mg four times a day), showed that isoxicam was statistically significantly better than aspirin in eight of 12 measures of efficacy. The study was carried out in 15 centers around the United States in 191 patients with classic or definite rheumatoid arthritis. The measures for which improvement with isoxicam was significantly better than aspirin were number of tender joints, sum of tenderness scores, number of swollen joints, sum of swelling scores, number of joints involved, grip strength, and overall assessment of the patient's condition by physician and patient. The measures for which the difference favoring isoxicam was not statistically significant were duration of morning stiffness, time to walk 50 feet, and global assessment of change in the patient's condition by physician and patient. The results indicate that 200 mg of isoxicam once daily is effective for treating rheumatoid arthritis. Compared with 3,600 mg of buffered aspirin daily, isoxicam is better in relief of symptoms and at least as effective regarding improvement in function.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000031:analogs & derivatives*; D013843:Thiazines / Q000627:therapeutic use*
D013843:Thiazines; D010894:Piroxicam; C013580:isoxicam; D001241:Aspirin